Issue Archive
Table of Contents
Inside Blood
Dasatinib, an immunomodulator?
In this issue of Blood, Kreutzman and colleagues describe the existence of clonal cytotoxic T and NK cells in over 80% (15 of 18) of patients with CML at diagnosis which persisted during treatment with the tyrosine kinase inhibitors, imatinib and dasatinib.1 Furthermore, they discovered that this clonal lymphocytosis expands further after therapy with dasatinib but not imatinib.
Union of forces advances myeloma care
In this issue of Blood, Richardson et al report on a landmark treatment regimen for newly diagnosed myeloma patients that for the first time combines lenalidomide and bortezomib. This effort required a team approach comprising 2 competing pharmaceutical companies (joining forces to study this promising regimen) and multiple academic medical centers.1
Rethinking warfarin reversal
Warfarin and other vitamin K antagonists are very effective for the treatment and prevention of both arterial and venous thromboembolism. Recombinant factor VIIa may not be as effective as previously thought for the urgent reversal of warfarin.
O tissue factor, where art thou?
In this issue of Blood, Pawlinski and colleagues identify myeloid cells and an unidentified nonhematopoietic cell(s) as the source of TF responsible for intravascular coagulation in a mouse model of endotoxemia, excluding a role for EC, VSMC, and platelet cell TF expression.1
Blood Work
Plenary Paper
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Perspectives
Clinical Trials and Observations
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Brief Report
Hematopoiesis and Stem Cells
Immunobiology
Lineage-specific T-cell reconstitution following in vivo CD4+ and CD8+ lymphocyte depletion in nonhuman primates
Lymphoid Neoplasia
Myeloid Neoplasia
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group
Clinical Trials & Observations
Platelets and Thrombopoiesis
Thrombosis and Hemostasis
Transplantation
Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma
Vascular Biology
RAGE and ICAM-1 cooperate in mediating leukocyte recruitment during acute inflammation in vivo
Correspondence
The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non–mast cell lineage disease (SM-AHNMD)
Errata
-
Cover Image
Cover Image
Angiogenesis is a physiologic process involving the growth of new blood vessels from preexisting ones. Angiogenesis is fundamental for organ growth, development, and wound healing, but is also associated with different diseases, such as cancer and retinopathy. This image represents a 3-dimensional reconstruction of a tissue macrophage interacting with a growing blood vessel in the brain. Michelangelo's masterpiece, shown in the background, depicts God's plan of creation, which is realized when God's finger extends toward Adam's hand. In a visually similar manner, the macrophage, labeled in green by a specific antibody, seems to contact a filopodial extension from the blood vessel, which is labeled in red with a lectin stain. See the article by Fantin et al on page 829.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals